Effective presentation of tumor antigens by dendritic cells (DCs) is considered to be essential for the induction of antitumor T-cell responses. Apoptotic and necrotic tumors have been noted to be a robust antigen source for DCs. Because glioma cells undergo apoptosis after transfection with the type I interferon (IFN) gene and type I IFNs promote the stimulatory activity of DCs, we hypothesized that transfection of glioma cells with type I IFN genes and provision of DCs would promote particularly effective antitumor activity by both facilitating apoptosis of glioma cells and the presentation of the glioma antigens, thereby inducing specific immune responses against glioma cells. We have previously reported the proof of this hypothesis in vitro and in a subcutaneous tumor model. Here we report an extension of this approach in intracranial (i.c.) gliomas using adenoviral IFN-a (Ad-IFN-a) vector. Mice bearing day-5 i.c. GL261 glioma received sequential intratumoral (i.t.) delivery of Ad-IFN-a and bone marrow-derived syngeneic DCs. This treatment prolonged survival in that nine of 17 animals survived long term (460 days versus 0 of 10 control animals). Specific CTL activity was demonstrated following this regimen in the cervical lymph nodes, and the therapeutic efficacy was dependent upon CD8+ cells. Furthermore, these animals were protected against subsequent rechallenge with GL261 gliomas. DCs injected i.t. survived in the tumor and migrated into cervical lymph node. In vitro migration assays revealed the ability of DCs to migrate toward the tumor, suggesting that i.t. injected DCs migrate through the glioma. Taken together, this combination of gene therapy and cellular immunotherapy may be an effective future strategy for treating human gliomas.
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Introduction
Immunological unresponsiveness of brain tumors may result in part from the paucity of functional antigen-presenting cells (APCs), such as dendritic cells (DCs), within the tumor microenvironment that are capable of effectively crosspriming specific T cells within the cervical lymph nodes (CLNs) as draining lymph nodes. CNS-derived DCs are typically weak stimulators of specific T-cell activation, 1 and have even been reported to exert suppressive influences on T-cell immunity. 2 Among the cytokines that can positively influence the function of APCs, type 1 interferons (IFNs), including IFN-a, -b, -d and -k, are attractive candidates for delivery into CNS tumors. 3, 4 The biological effects of type 1 IFNs on DCs include maturation 5, 6 and promotion of antigenpresenting ability. 7, 8 Recent studies demonstrated that IFN-a promotes crosspriming by increasing the expression of Transporters associated with Antigen Processing (TAP)-1 in DCs. 9 In addition, a critical role of type I IFNs in crosspriming of antigen-specific CTLs was directly demonstrated using IFN-a/b receptor-deficient mice. 8 Type I IFNs also directly inhibit proliferation of neoplastic cells through various mechanisms including induction of apoptotic cell death. [10] [11] [12] [13] It has also been reported that activation of DCs with IFN-a or -b leads to upregulation of TNF-a-related apoptosis-inducing ligand (TRAIL) expression, and to direct tumoricidal activity mediated by DCs via TRAIL.
14,15 IFN-a-transduced tumor cells also activate and promote the survival of tumor-specific CD8 + CTLs in vivo.
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Although the type I IFN protein has been used therapeutically for patients with malignant gliomas by systemic administration and its safety has been demonstrated, 17, 18 it has been difficult to achieve effective cytokine levels within the tumor at clinically tolerated doses. In an effort to target the expression of this cytokine to the tumor cells themselves, type I IFN gene transfer strategies have been examined in murine intracranial (i.c.) glioma models and have demonstrated preclinical efficacy. 19, 20 Effective presentation of tumor antigens by DCs is considered to be an essential step for effective induction of antitumor T-cell responses, and both necrotic 21 and apoptotic tumor cells [22] [23] [24] are known to be good antigen sources for DCs. We therefore hypothesized that transfection of glioma cells with IFN-a and provision of DCs would prove even more effective in driving antitumor immunity than IFN gene transfer alone, since this strategy would facilitate the apoptosis of glioma cells and prompt crosspresentation of glioma antigens by DCs to specific T cells.
Indeed, our previous study demonstrated the rapid induction of tumor-specific CTL responses in cultures consisting of live glioma cells, DCs and T cells following transfection with IFN-b. 11 In addition, in syngeneic animals bearing subcutaneous 203G gliomas, intratumoral (i.t.) injection of IFN-b gene and DCs led to the suppression of tumor growth and rejection of rechallenged 203G tumors at a distal site. 11 In the present study, we extended our strategy of sequential delivery of type 1 IFN gene and DCs in an i.c. glioma model. Our data provide a basis for effective modulation of the i.c. tumor microenvironment by cytokine gene therapy approaches combined with adoptive DC-based immunotherapeutic approaches.
Results
Transfection with Ad-IFN-a induces apoptotic cell death in a fraction of GL261 glioma cells in culture In order to examine whether adenoviral IFN-a gene transfer induces apoptotic death of GL261 glioma cells, we employed flow cytometric analyses for Annexin V binding and propidium iodide (PI) uptake. GL261 glioma cells were transfected with either Ad-IFNa or control Ad-LacZ, incubated at 371C for 72 h, and labeled with Annexin V and PI. Although there were constantly 4-10% Annexin V-positive GL261 glioma cells even with control Hank's balanced saline solution (HBSS) treatment (data not shown), Figure 1 demonstrates a specific increase of Annexin V-positive/PInegative and Annexin V-positive/PI-positive cells in comparison to the control cells that were treated with HBSS only. It was noted that IFN-a gene transfer resulted in the increase of apoptotic population in the cultured GL261 glioma cells, which were found as Annexin Vpositive/PI-negative or Annexin V-and PI-positive cells, each representing cells in the early or late phase of apoptotic death, respectively. 25 Ad-LacZ transfection resulted in only minimum increase of Annexin Vpositive cells, indicating that the induction of apoptosis was a specific effect of IFN-a transfection. Expression of IFN-a in this condition was determined by a specific enzyme-linked immunoabsorbance assay as approximately 300-400 ng/10 6 cells/72 h in all three separate experiments (data not shown).
Sequential delivery of Ad-IFN-a and DC in mice bearing i.c. GL261 tumors promotes a CD8+ cell-dependent, long-term antitumor immunity
To assess the therapeutic effects of this approach, mice bearing day-5 i.c. GL261 glioma first received i.t. delivery of Ad-IFN-a (1 Â 10 8 plaque forming units (PFU)), followed by a subsequent injection with syngeneic bone marrow (BM)-derived 1 Â 10 5 DCs on day 7. In control groups, Ad-IFN-a was replaced by a control Ad-LacZ and/or DC injection was replaced by HBSS injection. Figure 2a demonstrates that nine of 17 animals (52.9%) treated with both IFN-a gene delivery and subsequent DC injection survived longer than 60 days, and this combination significantly prolonged the survival in comparison to all other treatment groups (Po0.0001, P ¼ 0.0463 and P ¼ 0.0003 in comparison to AdLacZ+HBSS, Ad-IFN-a+HBSS and Ad-LacZ+DC groups, respectively). In contrast, all 10 control animals treated with Ad-LacZ and HBSS died by day 36. Treatment with Ad-IFN-a but not DCs resulted in only 23.5% (four of 17) prolonged survival (460 days), and combination of AdLacZ and DCs led to the prolonged survival of only one of 10 animals. Hence, a combinational therapy implementing the delivery of Ad-IFN-a and DCs into brain tumor sites may constitute a new therapeutic strategy to induce potent antiglioma immune responses.
In the next set of experiments, we evaluated whether CD4+ and/or CD8+ cell populations play critical roles in the anti-GL261 response induced by the combinational therapy with Ad-IFN-a and DCs. Animals that received Ad-IFN-a and DC as described above also received intraperitoneal (i.p.) injections of anti-CD4, CD8 monoclonal antibody, or PBS on days 1, 6 and 14 following the tumor inoculation. As demonstrated in Figure 2b , depletion of CD8+ cells completely abrogated antitumor efficacy induced by Ad-IFN-a and DC injections, with all animals in the group dying by day 40. Depletion of CD4+ cells resulted in long-term survival (460 days) in three of nine animals in the group, whereas five of nine animals that received Ad-IFN-a and DC therapy but no depletions survived longer than 60 days. Although there 
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T Tsugawa et al was a trend toward decreased therapeutic efficacy when the animals were depleted for CD4+ cells in comparison to the animals with no depletion, this difference did not reach statistical significance (P ¼ 0.2609). Indeed, in comparison to the group treated with Ad-LacZ and HBSS, the animals treated with Ad-IFN-a plus DC and depleted for CD4+ cells still demonstrated significant therapeutic effect (P ¼ 0.0061). These data strongly suggest that the combinational therapy with Ad-IFN-a and DC induced CD8+ effector cells that play a major role in the antitumor effect. In order to examine whether this combinational therapy induced long-term memory responses against i.c. GL261 gliomas, the animals that had survived following Ad-IFN-a plus DC treatment received a challenge with 1 Â 10 5 GL261 glioma cells in the contralateral (left) hemisphere on day 80 after the initial inoculation of GL261 cells in the right hemisphere. Control animals that had received no previous tumor inoculation or therapeutic injections received GL261 cell inoculation in the left hemisphere. Figure 2c demonstrates the survival period of animals after the tumor challenge in the left hemisphere. Two of four animals that received previous GL261 tumor and Ad-IFN-a plus DC treatment survived additional 60 days or longer, whereas all four control animals died by day 31. These data suggest that Ad-IFN-a plus DC treatment induced effective protective immunity against i.c. GL261 gliomas at least in some animals.
i.t. delivery of Ad-IFN-a promotes the persistence of DCs in the i.c. tumor microenvironment, and DCs migrate to CLNs following i.c. injections
We next assessed the impact of i.t. Ad-IFN-a delivery on the distribution of viable DCs that were subsequently transferred within the GL261 tumor microenvironment. Mice bearing an established day-14 i.c. GL261 glioma received i.t. injections with Ad-IFN-a or control AdLacZ. We generated BM-derived DCs from enhanced green fluorescent protein (EGFP)-transgenic mice (EGFP-DC), and injected 1 Â 10 5 EGFP-DCs i.t. 2 days after the adenoviral vector injections. Animals in another control group received HBSS instead of adenoviral vectors or EGFP-DCs. This treatment schedule with a larger tumor burden in comparison to therapy models (day 14 versus day 5 treatment) was selected to ascertain the location of the tumors in microscopic analyses. After 5 days, tumors were resected, fixed, sectioned and evaluated using twophoton fluorescence microscopy. As shown in Figure 3a i.c. Ad-IFN-a and DC delivery induces a specific antitumor CTL response in the CLNs
In order to examine whether the combinational treatment with Ad-IFN-a plus DCs resulted in the priming of tumor-specific T-cell immunity in the CLNs, mice bearing i.c. GL261 glioma received i.t. injections with Ad-IFN-a and DCs on days 5 and 7, respectively. The animals were killed on day 21 after tumor inoculation, and CLN cell suspensions were cultured in the presence of g-irradiated GL261 cells and low-dose (10 IU/ml) IL-2 for 5 days. CTL assays were performed using GL261 cells (Figure 4) . A remarkable level of CTL response against GL261 cells was observed in CLNs obtained from the animals treated with Ad-IFN-a and DCs. Omission of either IFN-a gene delivery or DCs abrogated the induction of cytotoxicity, suggesting that the combination of these components was required to elicit an optimal CTL response. These data support our hypothesis that delivery of IFN-a gene and DCs into the tumor microenvironment will promote specific anti-CNS tumor immunity. When taken together with the morphological data presented in Figure 3 , i.t. delivery of Ad-IFN-a appears to promote the migration and antigen-presenting function of DCs that were injected within the i.c. tumor site.
Attraction of DCs by glioma-derived factors in vitro
Our in vivo data evaluating migration of EGFP-DCs within the i.c. glioma suggest that at least a subset of the injected DCs may have migrated from the injection site to the periphery of the tumor mass. Considering future clinical translation of this approach, it is considered important to characterize whether injected DCs possess 'tropism' to gliomas so that injected DCs can infiltrate the tumor and promote the local antitumor immune response. To substantiate that DC recruitment is in response to tumor-derived factors, we analyzed the migratory activity of DCs to tumor-conditioned media using transwell chamber migration assays. The bottom chambers contained GL261-conditioned media serially diluted with basal media. DCs were plated on the upper chambers. Migration of DCs to the bottom side of transwell membranes was analyzed following a 4-h incubation. As demonstrated in Figure 5 , DCs migrated to the tumor-conditioned media in a dose-dependent manner, and 100% GL261-conditioned media enhanced the migration of DCs more than 2.5 times that observed in control base media. These results suggest that GL261 cells elaborate soluble substances that can attract DCs.
Discussion
In the present study, we demonstrate that (1) transfection with Ad-IFN-a induces apoptotic death of GL261 glioma cells in vitro, (2) sequential delivery of Ad-IFN-a and DC in the i.c. tumor site results in induction of a therapeutic and long-lasting antitumor CTL response, and (3) DCs that were generated for i.t. injections possess an ability to migrate toward GL261-derived soluble substances.
These results support our hypothesis that IFN-ainduced apoptotic tumor cells serve as a favorable 
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T Tsugawa et al antigen source for DCs, which are also activated by IFNa, thereby promoting effective induction of antitumor CTL responses. These results with an i.c. glioma model demonstrate a direct translation of our previous in vitro observations and in a subcutaneous glioma model, in which the combination of type I IFN gene delivery, DCs and T cells was required to elicit an effective antitumor CTL response. 11 Although a recent study using a rat 9L glioma and syngeneic BM-derived DCs demonstrated that i.t. DC injection induced specific T-cell reactivity against 9L, the level of response was rather modest. 26 Cytokine gene therapy for gliomas appears to have a promising future, based on encouraging results in murine models, 19, 27 although the efficacy in orthotopic i.c. models remains inferior to that observed in systemic tumor models. 28 This may reflect the fact that the central nervous system represents an immunologically challenging environment, 29, 30 at least partially due to a paucity of professional APCs under normal circumstances. 31 With regard to antigen presentation in the CNS and CNS tumors, although microglia are proposed to be resident APCs in the CNS, their capability for stimulating cellular immune responses is controversial (reviewed by Carson 32 and Graeber et al 33 ). In the case of experimental autoimmune encephalomyelitis (EAE), these CD11c+ cells exhibit a maturational phenotype similar to immature BM-derived DC or splenic DCs, and were unable to prime naïve T cells, and in some cases inhibited T-cell proliferation. 1 Gliomas in the brain may also attract and then functionally subvert APC function via tumor-associated factors such as IL-10, TGF-b2 and Fas-L. 2, [34] [35] [36] Our experiments using adoptively transferred EGFP-DCs demonstrated that few DCs remained within the i.c. tumor lesion by day 5 following Ad-LacZ injection. Although it is possible that these injected EGFP-DCs may have migrated out from the i.c. tumor site, these DCs induced only low magnitudes of CTL responses in the CLNs. Although GL261-conditioned media enhanced the migration of DCs in in vitro migration assays as a shortterm effect, based on our previous study, 37, 38 we think that the tumor microenvironment tends to induce apoptotic death of DCs in a long term. However, based on reported observations that IFN-a upregulates antiapoptotic molecules such as Bcl-2, Bcl-xL 39 and cellular FLICE inhibitory protein (cFLIP), 40 we are currently evaluating our hypothesis that delivery of IFN-a in the brain tumor environment promotes the survival of DCs through DC maturation and upregulation of antiapoptotic molecules.
With regard to the roles of IFN-a gene transfer and DCs in the induction of CTL responses, based on our in vitro results that a population of glioma cells undergoes apoptosis following Ad-IFN-a transfection, we believe that DCs may take up apoptotic tumor cells as a result of gene transfer, and that these antigen-loaded DCs may then crosspresent glioma-derived antigens to specific T cells in the draining lymph nodes. Indeed, our data showing the tumor-specific CTL response induced in the CLNs following the combination regimen clearly support this hypothesis. This is consistent with previous reports by others and us that have documented that DCs phagocytose apoptotic bodies and can effectively present antigens derived from these apoptotic bodies. 11, 22, 41 We are aware that endogenous APCs may also be activated by injection of Ad-IFN-a as well as by injected DCs. However, such endogenous microglia and macrophages in the tumor microenvironment are likely to be severely suppressed in their function due to the variety of mechanisms as discussed above. 29, 30, 32, 33, [42] [43] [44] Introduction of exogenously activated DCs that are cultured with GM-CSF and IL-4 may be necessary to overcome CNSand CNS tumor-induced suppression, as IL-4 prevents the blockade of DC differentiation induced by tumor cells. 45 This hypothesis is in accord with our observation that the combination delivery of Ad-IFN-a and exogenously activated DC was superior to the Ad-IFN-a and HBSS regimen in both therapeutic and immunological end points.
Lastly, we also demonstrated using two-chamber assays that GL261 glioma cells secrete chemo-attractive substances that can stimulate the migratory response of DCs. While further studies are warranted to identify the molecules that are responsible for the chemo-attraction of DCs, this characteristic makes DCs attractive vehicles for delivery of therapeutic molecules to infiltrative elements of gliomas. We hypothesize that glioma-derived chemokines such as RANTES 46, 47 and MCP-1 48 play major roles in attracting immature DCs because immature DCs express corresponding receptors for these chemokines such as CCR1. 49 As to the maturation stage of DCs, we used relatively immature DCs that were derived from BM and cultured in the presence of GM-CSF and IL-4 for 7 days, since immature DCs are believed to be efficient in taking up foreign antigens by phagocytosis. 23, 41, 50 Based on in vitro and in vivo data in the present study, we hypothesize that immature DCs may be attracted to the tumor site, where they may take up antigens, and after undergoing maturation and changes in chemokine receptors, they may migrate to the CLNs.
While not yet investigated in the present study, uptake of apoptotic tumor bodies may trigger DC expression of the secondary lymphoid tissue homing receptor, CCR7. Migration of DCs to tumor-conditioned media in vitro. DCs generated by 7-day culture of BM cells with GM-CSF and IL-4 were analyzed for their migratory responses to GL261-conditioned medium using two-chamber migration assays. The graph indicates relative numbers of DCs detected in the bottom chambers in comparison to migration to control media. The pictures demonstrate DCs that migrated to the bottom side of the transwell membranes by Wright-Giemsa staining. Po0.05 at 50 and 100% against conditioned media.
Glioma gene therapy with IFN-a and DCs T Tsugawa et al injected DCs that remain in the tumor site may also play crucial roles in recruiting and presenting tumor antigens to infiltrating T cells. We are currently analyzing the phenotypes and maturation stages of DCs that respond and do not respond to GL261-conditioned media and are attempting to identify tumor-derived agents that are critical for the tumor-tropic migratory response.
Our data in the present study provide new insights into the development of future strategies to modify the brain tumor microenvironment in order to induce effective antitumor immunity through the combined delivery of the IFN-a gene and DCs. In addition, the combination of this approach with peripheral vaccine strategies may further enhance therapeutic efficacy by promoting the activity and survival of immune effector cells, which are primarily induced in the periphery. [51] [52] [53] Materials and methods
Animals
Female 6-to 8-week-old C57BL/6 mice and C57BL/6 background transgenic mice line expressing EGFP C57BL/6-TgN(ACTbEGFP)1Osb were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Animals were handled under aseptic conditions in microisolator cages within the Central Animal Facility at the University of Pittsburgh as per the Institutional Animal Care and Use Committee-approved protocol, and in accordance with recommendations for proper care and use of laboratory animals.
Cell lines and culture
Mouse glioma cell line GL261 (H-2 b ) was kindly provided by Dr Jun Yoshida (Nagoya University, Japan). 19 Cell lines were cultured in complete medium (CM; RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 10 mM L-glutamine (all reagents from Life Technologies Inc., Grand Island, NY, USA)) in a humidified incubator in 5% CO 2 at 371C.
Generation of DCs from BM
The procedure used in this study was previously described. 53 Briefly, C57BL/6 or EGFP-transgenic C57BL/6 mouse-derived BM cells were cultured in CM supplemented with 1000 U/ml recombinant murine granulocyte/macrophage colony-stimulating factor and recombinant mIL-4 (Schering-Plough, Kenilworth, NJ, USA) at 371C in a humidified, 5% CO 2 incubator for 7 days. DCs were then isolated at the interface of 14.5% (w/v) metrizamide (Sigma, St Louis, MO, USA) in CM discontinuous gradients by centrifugation. DCs typically represented 490% of the harvested population of cells based on morphology and expression of the CD11b, CD11c, CD40, CD54, CD80, CD86, and class I and class II MHC antigens (data not shown).
Viral vectors
The adenoviral vector (Ad) encoding mouse IFN-a gene (Ad-IFN-a) and control Ad encoding b-galactosidase (Ad-LacZ) were produced and provided by the University of Pittsburgh Cancer Institute's Vector Core Facility as reported previously. 38 Flow cytometric analyses of apoptotic cell death GL261 glioma cells grown in CM were washed with PBS in T-25 flasks, and co-incubated with adenoviral vector at a multiplicity of infection (MOI) of 50 in 2 ml, for 2 h at room temperature. CM (9 ml) was then added to each flask, and the cells were cultured in 5% CO 2 at 371C for 72 h. Induction of apoptotic cell death was then analyzed by Annexin V binding assay and PI uptake evaluation. The cells were collected and double stained with FITCconjugated Annexin V (PharMingen) and/or 10 mg/ml PI (Sigma). A total of 5000 cells were analyzed with no gating of cells using a FACScan or FACScan Plus cytometer (Becton Dickinson Inc., Mountain View, CA, USA). FACS data analyses were performed using REPROMAN software (True Facts Software, Seattle, WA, USA).
Tumor inoculation and intratumoral delivery of Ad-IFN-a and DCs
Animals received an i.c. injection of GL261 glioma cells as previously described. 53 Briefly, using a 10 ml Hamilton syringe, 1 Â 10 5 GL261 suspended in 2 ml of HBSS were stereotactically injected at the bregma 2 mm to the right of the sagittal suture and 3 mm below the surface of the skull of anesthetized C57BL/6 mice using a Kopf stereotactic frame (Kopf Instruments, Tujunga, CA, USA). The animals bearing i.c. tumors received an i.t. injection with 1 Â 10 8 PFU Ad-IFN-a or control Ad-LacZ in the same location on day 5 following the i.c. tumor challenge. The animals also received i.t. injections with 1 Â 10 5 DCs or HBSS at the same coordinates on day 7. The animals were monitored daily after treatment for the manifestation of any pathologic signs associated with elevated i.c. pressure, such as hemiparesis, loss of appetite or any altered grooming habits. Affected animals were killed by CO 2 inhalation. Representative animals in each treatment cohort were killed at selected time points to obtain tissues (brain tumors, lymphoid organs) for immunological analyses.
T-cell depletion experiments
On days 1, 6 and 14 after tumor inoculation, mice received i.p. injections containing 50 ml of ascitic fluid of anti-CD4 (GK1.5 hybridoma; ATCC, Manassas, VA, USA), anti-CD8 (53-6.72 hybridoma; ATCC), or PBS. The efficiency of specific subset depletions was validated by flow cytometry analysis of splenocytes (SPCs) using PEconjugated anti-CD4 and anti-CD8 mAbs (BD PharMingen). In all cases, 99% of the targeted cell subset was specifically depleted (data not shown).
Microscopic analyses of the tumor tissues and CLNs
To assess the trafficking of DCs microscopically, day-7 BM-derived EGFP-DCs were purified as indicated above, and injected into day-16 i.c. GL261 tumors established in syngeneic C57BL/6 mice that had received i.t. injections with Ad-IFN-a or Ad-LacZ on day 14. Brain tissues and CLNs were removed at 5 days after EGFP-DC injection and fixed with 4% paraformaldehyde. Sections (1 mm) were imaged for EGFP-DCs using a two-photon microscope comprising a titanium-sapphire ultrafast tunable laser system (Coherent Mira Model 900-F), Olympus Fluoview confocal scanning electronics, an Olympus IX70 inverted system microscope, and custom-built 
CTL activity assay
Animals received syngeneic 1 Â 10 5 GL261 cells on day 0. Following injections with adenoviral vectors and DCs on days 5 and 7, respectively, CLNs were resected on day 21 and single-cell suspensions were cultured at 2 Â 10 6 cells/ml with g-irradiated (50 Gy) GL261 in the presence of 10 U/ml human IL-2 (Chiron, Emeryville, CA, USA), 50 mM 2-mercaptoethanol (Sigma, St Louis, MO, USA) and 50 mM N G -monomethyl-L-arginine (Cyclopss, Salt Lake City, UT, USA) in 24-well plates (Corning, Corning, NY, USA) for 5 days. Specific CTL activity was determined in 4 h 51 Cr release assays against GL261 cells, as previously described.
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Migration assays DC migration was determined using 48-well microchemotaxis chamber assay as described previously. 54, 55 Cell migration was quantified by the number of cells that migrated directionally through a fibronectin-coated 8-mm-pore polyvinyl pyrolidone-free polycarbonate filter (Corning Coster, Cambridge, MA, USA) toward the lower wells. Briefly, DCs (1 Â 10 6 cells/ml) were resuspended in serum-free RPMI 1640 containing 0.1% BSA. The lower wells contained either base media (RPMI containing 0.1% BSA) or tumor cell-conditioned media (RPMI containing 0.1% BSA with which tumor cells had been cultured for 48 h) at serial dilutions with the base media. Chambers were incubated at 371C in a humidified incubator in an atmosphere of 5% CO 2 for 4 h, after which the filters were removed, fixed, Wright-Giemsa stained and mounted on glass slides. Nonmigrating cells were removed by wiping with a cotton swab. At least five random fields of vision/well (at a total magnification of Â 200) were counted for quantification of cell migration. Each group was analyzed in triplicate, and relative cell numbers in comparison to the average of controls (base media group) were calculated.
Statistical analysis
Survival estimates and median survival times were determined using the method of Kaplan and Meier. Survival data were compared using a log-rank test. Comparative values from in vitro assays were compared by Student's t-test for two samples with unequal variances. Statistical significance was determined at the o0.05 level.
